Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 447 entries
Sorted by: Best Match Show Resources per page
Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats.

Journal of anesthesia

Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A.
PMID: 14566514
J Anesth. 2001;15(3):154-8. doi: 10.1007/s005400170018.

PURPOSE: For assessment of the antinociceptive potency of antidepressants, we compared the antinociceptive effects of serotonin selective reuptake inhibitors (SSRIs) and classical tricyclic antidepressants (TCAs) in rats. We also attempted to elucidate the monoamine receptor subtypes predominantly involved in...

Cite
Otsuka N, Kiuchi Y, Yokogawa F, et al. Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth. 2001;15(3):154-8doi: 10.1007/s005400170018.
Otsuka, N., Kiuchi, Y., Yokogawa, F., Masuda, Y., Oguchi, K., & Hosoyamada, A. (2001). Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. Journal of anesthesia, 15(3), 154-8. https://doi.org/10.1007/s005400170018
Otsuka, N, et al. "Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats." Journal of anesthesia vol. 15,3 (2001): 154-8. doi: https://doi.org/10.1007/s005400170018
Otsuka N, Kiuchi Y, Yokogawa F, Masuda Y, Oguchi K, Hosoyamada A. Antinociceptive efficacy of antidepressants: assessment of five antidepressants and four monoamine receptors in rats. J Anesth. 2001;15(3):154-8. doi: 10.1007/s005400170018. PMID: 14566514.
Copy Download .nbib Format: NLM
QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy.

Annals of general psychiatry

Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM.
PMID: 15845138
Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1.

BACKGROUND: Several antipsychotic agents are known to prolong the QT interval in a dose dependent manner. Corrected QT interval (QTc) exceeding a threshold value of 450 ms may be associated with an increased risk of life threatening arrhythmias. Antipsychotic...

Cite
Sala M, Vicentini A, Brambilla P, et al. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005;4(1):1doi: 10.1186/1744-859X-4-1.
Sala, M., Vicentini, A., Brambilla, P., Montomoli, C., Jogia, J. R., Caverzasi, E., Bonzano, A., Piccinelli, M., Barale, F., & De Ferrari, G. M. (2005). QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Annals of general psychiatry, 4(1), 1. https://doi.org/10.1186/1744-859X-4-1
Sala, Michela, et al. "QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy." Annals of general psychiatry vol. 4,1 (2005): 1. doi: https://doi.org/10.1186/1744-859X-4-1
Sala M, Vicentini A, Brambilla P, Montomoli C, Jogia JR, Caverzasi E, Bonzano A, Piccinelli M, Barale F, De Ferrari GM. QT interval prolongation related to psychoactive drug treatment: a comparison of monotherapy versus polytherapy. Ann Gen Psychiatry. 2005 Jan 25;4(1):1. doi: 10.1186/1744-859X-4-1. PMID: 15845138; PMCID: PMC1088007.
Copy Download .nbib Format: NLM
Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study.

The primary care companion for CNS disorders

Thase ME, Ninan PT, Musgnung JJ, Trivedi MH.
PMID: 21731835
Prim Care Companion CNS Disord. 2011;13(1). doi: 10.4088/PCC.10m00979blu.

BACKGROUND: This randomized, open-label, rater-blinded, multicenter study compared treatment outcomes with the serotonin-norepinephrine reuptake inhibitor (SNRI) venlafaxine extended release (ER) with selective serotonin reuptake inhibitors (SSRIs) in primary care patients with major depressive disorder.METHOD: Study data were collected from...

Cite
Thase ME, Ninan PT, Musgnung JJ, et al. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord. 2011;13(1)doi: 10.4088/PCC.10m00979blu.
Thase, M. E., Ninan, P. T., Musgnung, J. J., & Trivedi, M. H. (2011). Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. The primary care companion for CNS disorders, 13(1), . https://doi.org/10.4088/PCC.10m00979blu
Thase, Michael E, et al. "Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study." The primary care companion for CNS disorders vol. 13,1 (2011). doi: https://doi.org/10.4088/PCC.10m00979blu
Thase ME, Ninan PT, Musgnung JJ, Trivedi MH. Remission with venlafaxine extended release or selective serotonin reuptake inhibitors in depressed patients: a randomized, open-label study. Prim Care Companion CNS Disord. 2011;13(1). doi: 10.4088/PCC.10m00979blu. PMID: 21731835; PMCID: PMC3121209.
Copy Download .nbib Format: NLM
Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin.

Evidence-based mental health

Mansfield JK, Kennedy SH.
PMID: 20682829
Evid Based Ment Health. 2010 Aug;13(3):89. doi: 10.1136/ebmh.13.3.89.

No abstract available.

Cite
Mansfield JK, Kennedy SH. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. Evid Based Ment Health. 2010;13(3):89doi: 10.1136/ebmh.13.3.89.
Mansfield, J. K., & Kennedy, S. H. (2010). Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. Evidence-based mental health, 13(3), 89. https://doi.org/10.1136/ebmh.13.3.89
Mansfield, Joanna K, and Kennedy, Sidney H. "Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin." Evidence-based mental health vol. 13,3 (2010): 89. doi: https://doi.org/10.1136/ebmh.13.3.89
Mansfield JK, Kennedy SH. Current use of venlafaxine not associated with excess risk of sudden cardiac death or near death compared with fluoxetine, citalopram or dosulepin. Evid Based Ment Health. 2010 Aug;13(3):89. doi: 10.1136/ebmh.13.3.89. PMID: 20682829.
Copy Download .nbib Format: NLM
Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases.

European psychiatry : the journal of the Association of European Psychiatrists

Koponen H, Lepola H, Leinonen E.
PMID: 19698341
Eur Psychiatry. 1995;10(4):209-10. doi: 10.1016/0767-399X(96)80066-6.

No abstract available.

Cite
Koponen H, Lepola H, Leinonen E. Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases. Eur Psychiatry. 1995;10(4):209-10doi: 10.1016/0767-399X(96)80066-6.
Koponen, H., Lepola, H., & Leinonen, E. (1995). Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases. European psychiatry : the journal of the Association of European Psychiatrists, 10(4), 209-10. https://doi.org/10.1016/0767-399X(96)80066-6
Koponen, H, et al. "Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases." European psychiatry : the journal of the Association of European Psychiatrists vol. 10,4 (1995): 209-10. doi: https://doi.org/10.1016/0767-399X(96)80066-6
Koponen H, Lepola H, Leinonen E. Citalopram in the treatment of obsessive-compulsive disorder. A report of two cases. Eur Psychiatry. 1995;10(4):209-10. doi: 10.1016/0767-399X(96)80066-6. PMID: 19698341.
Copy Download .nbib Format: NLM
Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.

Expert review of pharmacoeconomics & outcomes research

Lam RW, Annemans L.
PMID: 20528319
Expert Rev Pharmacoecon Outcomes Res. 2007 Dec;7(6):559-76. doi: 10.1586/14737167.7.6.559.

In addition to the large personal challenge that depression and anxiety present, these disorders are associated with a substantial burden of disability and lost productivity, and are responsible for considerable strain on healthcare resources and on society. Escitalopram is...

Cite
Lam RW, Annemans L. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res. 2007;7(6):559-76doi: 10.1586/14737167.7.6.559.
Lam, R. W., & Annemans, L. (2007). Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert review of pharmacoeconomics & outcomes research, 7(6), 559-76. https://doi.org/10.1586/14737167.7.6.559
Lam, Raymond W, and Annemans, Lieven. "Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders." Expert review of pharmacoeconomics & outcomes research vol. 7,6 (2007): 559-76. doi: https://doi.org/10.1586/14737167.7.6.559
Lam RW, Annemans L. Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res. 2007 Dec;7(6):559-76. doi: 10.1586/14737167.7.6.559. PMID: 20528319.
Copy Download .nbib Format: NLM
[Chiral separation of citalopram intermediate compounds by CE].

Se pu = Chinese journal of chromatography

Jiang J, Xu H, Chen Z, Xiao S, Xia Z.
PMID: 17288158
Se Pu. 2006 Nov;24(6):657.

No abstract available.

Cite
Jiang J, Xu H, Chen Z, et al. [Chiral separation of citalopram intermediate compounds by CE]. Se Pu. 2006;24(6):657
Jiang, J., Xu, H., Chen, Z., Xiao, S., & Xia, Z. (2006). [Chiral separation of citalopram intermediate compounds by CE]. Se pu = Chinese journal of chromatography, 24(6), 657.
Jiang, Junpo, et al. "[Chiral separation of citalopram intermediate compounds by CE]." Se pu = Chinese journal of chromatography vol. 24,6 (2006): 657.
Jiang J, Xu H, Chen Z, Xiao S, Xia Z. [Chiral separation of citalopram intermediate compounds by CE]. Se Pu. 2006 Nov;24(6):657. Chinese. PMID: 17288158.
Copy Download .nbib Format: NLM
Using functional behavioral assessment to study the effects of citalopram on the obsessive-compulsive verbalizations of a woman with obsessive-compulsive disorder and mental retardation.

Primary care companion to the Journal of clinical psychiatry

May ME, Jackson JA, Blodgett KA, Huber HB, Kishel EK, Riediger AB, Kennedy CH.
PMID: 18311429
Prim Care Companion J Clin Psychiatry. 2008;10(1):73-5. doi: 10.4088/pcc.v10n0113d.

No abstract available.

Cite
May ME, Jackson JA, Blodgett KA, et al. Using functional behavioral assessment to study the effects of citalopram on the obsessive-compulsive verbalizations of a woman with obsessive-compulsive disorder and mental retardation. Prim Care Companion J Clin Psychiatry. 2008;10(1):73-5doi: 10.4088/pcc.v10n0113d.
May, M. E., Jackson, J. A., Blodgett, K. A., Huber, H. B., Kishel, E. K., Riediger, A. B., & Kennedy, C. H. (2008). Using functional behavioral assessment to study the effects of citalopram on the obsessive-compulsive verbalizations of a woman with obsessive-compulsive disorder and mental retardation. Primary care companion to the Journal of clinical psychiatry, 10(1), 73-5. https://doi.org/10.4088/pcc.v10n0113d
May, Michael E, et al. "Using functional behavioral assessment to study the effects of citalopram on the obsessive-compulsive verbalizations of a woman with obsessive-compulsive disorder and mental retardation." Primary care companion to the Journal of clinical psychiatry vol. 10,1 (2008): 73-5. doi: https://doi.org/10.4088/pcc.v10n0113d
May ME, Jackson JA, Blodgett KA, Huber HB, Kishel EK, Riediger AB, Kennedy CH. Using functional behavioral assessment to study the effects of citalopram on the obsessive-compulsive verbalizations of a woman with obsessive-compulsive disorder and mental retardation. Prim Care Companion J Clin Psychiatry. 2008;10(1):73-5. doi: 10.4088/pcc.v10n0113d. PMID: 18311429; PMCID: PMC2249832.
Copy Download .nbib Format: NLM
Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice.

Indian journal of pharmacology

Kumar A, Garg R, Gaur V, Kumar P.
PMID: 21713041
Indian J Pharmacol. 2011 May;43(3):324-9. doi: 10.4103/0253-7613.81506.

BACKGROUND AND OBJECTIVE: The present study was designed to elucidate the possible nitric oxide (NO) mechanism in the protective effect of antidepressants using mice model of chronic fatigue syndrome (CFS).MATERIALS AND METHODS: Male albino laca mice were forced to...

Cite
Kumar A, Garg R, Gaur V, et al. Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice. Indian J Pharmacol. 2011;43(3):324-9doi: 10.4103/0253-7613.81506.
Kumar, A., Garg, R., Gaur, V., & Kumar, P. (2011). Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice. Indian journal of pharmacology, 43(3), 324-9. https://doi.org/10.4103/0253-7613.81506
Kumar, Anil, et al. "Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice." Indian journal of pharmacology vol. 43,3 (2011): 324-9. doi: https://doi.org/10.4103/0253-7613.81506
Kumar A, Garg R, Gaur V, Kumar P. Nitric oxide modulation in protective role of antidepressants against chronic fatigue syndrome in mice. Indian J Pharmacol. 2011 May;43(3):324-9. doi: 10.4103/0253-7613.81506. PMID: 21713041; PMCID: PMC3113388.
Copy Download .nbib Format: NLM
Marked mydriasis and neuritis nervi optici associated with galactorrhea following citalopram treatment: a case report and discussion.

Case reports in medicine

Koch HJ, Zellmer H.
PMID: 21869891
Case Rep Med. 2011;2011:191735. doi: 10.1155/2011/191735. Epub 2011 Aug 15.

We report the case of a 25-year-old women suffering from major depression who was treated with citalopram for several weeks with doses between 20 mg and 60 mg. She gradually developed marked mydriasis within 2 months after treatment and...

Cite
Koch HJ, Zellmer H. Marked mydriasis and neuritis nervi optici associated with galactorrhea following citalopram treatment: a case report and discussion. Case Rep Med. 2011;2011:191735doi: 10.1155/2011/191735.
Koch, H. J., & Zellmer, H. (2011). Marked mydriasis and neuritis nervi optici associated with galactorrhea following citalopram treatment: a case report and discussion. Case reports in medicine, 2011191735. https://doi.org/10.1155/2011/191735
Koch, Horst J, and Zellmer, Heike. "Marked mydriasis and neuritis nervi optici associated with galactorrhea following citalopram treatment: a case report and discussion." Case reports in medicine vol. 2011 (2011): 191735. doi: https://doi.org/10.1155/2011/191735
Koch HJ, Zellmer H. Marked mydriasis and neuritis nervi optici associated with galactorrhea following citalopram treatment: a case report and discussion. Case Rep Med. 2011;2011:191735. doi: 10.1155/2011/191735. Epub 2011 Aug 15. PMID: 21869891; PMCID: PMC3160104.
Copy Download .nbib Format: NLM
Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.

American health & drug benefits

Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.
PMID: 25126340
Am Health Drug Benefits. 2011 Mar;4(2):78-87.

BACKGROUND: Major depressive disorder is the most common type of depression, affecting 6.6% of adults in the United States annually. Citalopram and escitalopram are common second-generation antidepressants used for the treatment of patients with this disorder. Because citalopram is...

Cite
Wu EQ, Greenberg PE, Ben-Hamadi R, et al. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. Am Health Drug Benefits. 2011;4(2):78-87
Wu, E. Q., Greenberg, P. E., Ben-Hamadi, R., Yu, A. P., Yang, E. H., & Erder, M. H. (2011). Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. American health & drug benefits, 4(2), 78-87.
Wu, Eric Q, et al. "Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram." American health & drug benefits vol. 4,2 (2011): 78-87.
Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH. Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram. Am Health Drug Benefits. 2011 Mar;4(2):78-87. PMID: 25126340; PMCID: PMC4106579.
Copy Download .nbib Format: NLM
Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use.

Indian journal of psychiatry

Kirpekar VC, Joshi PP.
PMID: 20711296
Indian J Psychiatry. 2005 Apr;47(2):119-20. doi: 10.4103/0019-5545.55960.

Selective serotonin reuptake inhibitors (SSRIs) can cause the syndrome of inappropriate antidiuretic hormone secretion (SIADH). SIADH is associated with hyponatraemia without oedema. We report the case of a patient who developed acute-onset hyponatraemia that progressed rapidly to serious neurological...

Cite
Kirpekar VC, Joshi PP. Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use. Indian J Psychiatry. 2005;47(2):119-20doi: 10.4103/0019-5545.55960.
Kirpekar, V. C., & Joshi, P. P. (2005). Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use. Indian journal of psychiatry, 47(2), 119-20. https://doi.org/10.4103/0019-5545.55960
Kirpekar, Vivek C, and Joshi, Prashant P. "Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use." Indian journal of psychiatry vol. 47,2 (2005): 119-20. doi: https://doi.org/10.4103/0019-5545.55960
Kirpekar VC, Joshi PP. Syndrome of inappropriate ADH secretion (SIADH) associated with citalopram use. Indian J Psychiatry. 2005 Apr;47(2):119-20. doi: 10.4103/0019-5545.55960. PMID: 20711296; PMCID: PMC2918297.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 447 entries